BTTX

Better Therapeutics, Inc. [BTTX] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

BTTX Stock Summary

Top 10 Correlated Stocks

BTTX

In the News

BTTX Financial details

Company Rating
-
Market Cap
648.74K
Income
-31.57M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
54
Optionable
No
Shortable
Yes
Earnings
12 Apr 2024
P/E
-0.28
Forward P/E
-
PEG
0.09
P/S
-
P/B
-0.89
P/C
-
P/FCF
-0.42
Quick Ratio
0.51
Current Ratio
0.57
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.15
EPS next Y
-
EPS next Q
-
EPS this Y
-1.17%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-37.5%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-294%
ROE
401%
ROC
13.36%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.005-1.55
52W High
-
52W Low
-
RSI
89.2
Rel Volume
-
Avg Volume
6.13M
Volume
600
Perf Week
200%
Perf Month
200%
Perf Quarter
-
Perf Half Y
200%
-
-
-
-
Beta
2.131
-
-
Volatility
0%, 0%
Prev Close
50%
Price
0.0003
Change
50%

Something similar

Top by Market Cap
EMBASSY.NS
3V64.DE
M&M.NS
JPM
MIX.JO
Same Sector
DNTL.TO
AZRX
LJPC
1763.HK
FRX.TO
Top Correlated Stocks
HOCN.SW
ONCO3.SA
SMGI
NVAC
FSPORT.ST
Similar Market Cap
IVDG
HPAC.L
NVACR
OTIC
HMJU.TO

Company Profile

Healthcare Biotechnology
  • Volume Average 6.13M
  • Market Capitalization 648.74K
  • Employee 54
  • CEO Mr. Frank L. Karbe
  • Headquarters San Francisco,CA,US
  • IPO Date 2021-03-17
  • Website https://www.bettertx.com

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.